US5534263A
(en)
*
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
CA2173818A1
(fr)
*
|
1996-04-10 |
1997-10-11 |
Francois Chouinard |
Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
|
US5804165A
(en)
*
|
1996-07-24 |
1998-09-08 |
Arnold; Michael J. |
Antiplaque oral composition
|
DE19640062B4
(de)
*
|
1996-09-28 |
2006-04-27 |
Lts Lohmann Therapie-Systeme Ag |
Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
IT1294760B1
(it)
*
|
1997-09-03 |
1999-04-12 |
Jagotec Ag |
Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
|
IN186245B
(pt)
*
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
GB9724186D0
(en)
|
1997-11-14 |
1998-01-14 |
British Tech Group |
Low temperature coatings
|
IL136549A
(en)
*
|
1997-12-22 |
2005-05-17 |
Schering Corp |
Orally administrable solid ribavirin dosage forms and process for making them
|
IL139590A0
(en)
*
|
1998-06-05 |
2002-02-10 |
Warner Lambert Co |
Stabilization of compositions containing ace inhibitors using magnesium oxide
|
IL141339A0
(en)
*
|
1998-09-25 |
2002-03-10 |
Delsys Pharmaceutical Corp |
Liquid pharmaceutical for oral delivery
|
ATE424810T1
(de)
|
1998-12-11 |
2009-03-15 |
Nostrum Pharmaceuticals Inc |
Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
FR2797185B1
(fr)
*
|
1999-08-06 |
2001-10-26 |
Galenix Dev |
Composition pharmaceutique flottante comprenant une phase active et une phase non active
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
JP4565456B2
(ja)
*
|
1999-11-02 |
2010-10-20 |
塩野義製薬株式会社 |
着色顆粒の色素定着法
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
AR030557A1
(es)
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
US6955821B2
(en)
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
MXPA02012793A
(es)
*
|
2000-06-23 |
2004-07-30 |
Teva Pharmaceuticals Ltd |
Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US6881420B2
(en)
*
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
DE10031043A1
(de)
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
WO2003097018A1
(en)
*
|
2002-02-04 |
2003-11-27 |
Ranbaxy Laboratories Limited |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
EP1347748A2
(en)
*
|
2000-12-05 |
2003-10-01 |
MacGregor, Alexander |
Hydrostatic delivery system for controlled delivery of agent
|
KR100685945B1
(ko)
|
2000-12-29 |
2007-02-23 |
엘지.필립스 엘시디 주식회사 |
액정표시장치 및 그 제조방법
|
US8268333B2
(en)
*
|
2001-04-24 |
2012-09-18 |
Lintec Corporation |
Orally administered agent and an orally administered agent/supporting substrate complex
|
DE10120092B4
(de)
*
|
2001-04-25 |
2008-03-20 |
Lts Lohmann Therapie-Systeme Ag |
Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
|
IL159812A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
|
IL159813A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
AU2002340470A1
(en)
|
2001-11-13 |
2003-05-26 |
Teva Pharmaceutical Industries, Ltd. |
L-dopa ethyl ester salts and uses thereof
|
US20030135065A1
(en)
*
|
2001-11-13 |
2003-07-17 |
Ramy Lidor-Hadas |
Process for the production of L-DOPA ethyl ester
|
US6645526B2
(en)
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
WO2003053450A1
(de)
*
|
2001-12-21 |
2003-07-03 |
Biopartners Gmbh |
Ribavirin-granulat zur herstellung von filmtabletten
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
WO2004026283A1
(en)
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sequestering subunit and related compositions and metohds
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
US20040091538A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Crystal Pollock-Dove |
Dosage form providing ascending release of liquid formulation
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
WO2005058319A1
(en)
|
2003-12-16 |
2005-06-30 |
Cnsbio Pty Ltd |
Methods and compositions
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
WO2005084703A1
(ja)
*
|
2004-03-09 |
2005-09-15 |
Nrl Pharma, Inc. |
徐放性の口腔用組成物
|
FR2874325B1
(fr)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
|
JP5046946B2
(ja)
*
|
2004-10-15 |
2012-10-10 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
低乱用性薬学的製剤
|
KR20130115401A
(ko)
*
|
2004-11-19 |
2013-10-21 |
글락소스미스클라인 엘엘씨 |
약제학적 제품
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
AU2005320547B2
(en)
*
|
2004-12-27 |
2009-02-05 |
Eisai R & D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
AU2006261893A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Combinatorx, Incorporated |
Improved dosage forms for movement disorder treatment
|
AU2006263338A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Panacea Biotec Ltd. |
Pharmaceutical sustained release compositions and processes thereof
|
KR101655455B1
(ko)
*
|
2005-09-09 |
2016-09-07 |
안젤리니 라보팜 엘엘씨 |
일일 1회 투여를 위한 트라조돈 조성물
|
NL2000281C2
(nl)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Vaste farmaceutische samenstellingen die pregabaline bevatten.
|
WO2007072495A2
(en)
*
|
2005-11-03 |
2007-06-28 |
Sun Pharmaceutical Industries Limited |
Coated tablets having prolonged gastric retention
|
WO2007056570A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Teva Pharmaceutical Industries Ltd. |
Levodopa compositions
|
US7674396B2
(en)
*
|
2005-11-08 |
2010-03-09 |
Plensat Llc |
Method and system for treatment of eating disorders
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
KR100752417B1
(ko)
*
|
2006-02-14 |
2007-08-28 |
대원제약주식회사 |
안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
CN101484165A
(zh)
*
|
2006-05-03 |
2009-07-15 |
Cns生物有限公司 |
治疗炎性疼痛的方法与组合物
|
US20100297226A1
(en)
*
|
2006-06-01 |
2010-11-25 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
US8158156B2
(en)
|
2006-06-19 |
2012-04-17 |
Alpharma Pharmaceuticals, Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
US9101544B2
(en)
*
|
2006-08-30 |
2015-08-11 |
Jagotec Ag |
Controlled release nisoldipine compositions
|
WO2008039186A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
WO2008039193A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
US20080181947A1
(en)
*
|
2006-09-26 |
2008-07-31 |
Astellas Pharma Inc. |
Controlled release dosage form of tacrolimus
|
EP1935411A1
(en)
|
2006-12-15 |
2008-06-25 |
Campina Nederland Holding B.V. |
Slow release excipient and its use
|
EP2063867A2
(en)
*
|
2006-12-22 |
2009-06-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
WO2008084698A1
(ja)
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
タクロリムス徐放性医薬組成物
|
AT505225A1
(de)
*
|
2007-04-26 |
2008-11-15 |
Sanochemia Pharmazeutika Ag |
0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
KR20110025833A
(ko)
*
|
2008-06-16 |
2011-03-11 |
아피언 랍스, 엘엘씨 |
활성제의 일정한 (0-차) 방출을 위한 방출 시스템의 조성물 및 제조방법
|
EP2326310B1
(en)
*
|
2008-08-15 |
2019-05-15 |
Assertio Therapeutics, Inc. |
Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
|
CA2739246A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Bioplus Life Sciences Pvt. Ltd. |
Sustained release drug delivery system
|
US20100112054A1
(en)
*
|
2008-10-23 |
2010-05-06 |
Appian Labs, Llc |
Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
EP2210585A1
(en)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
SPRM pharmaceutical compositions methods of treatment using them
|
US20100249423A1
(en)
*
|
2009-03-09 |
2010-09-30 |
Sanochemia Pharmazeutika Ag |
Tolperisone controlled release tablet
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
WO2011078993A1
(en)
|
2009-12-21 |
2011-06-30 |
Aptapharma, Inc. |
Functionally-coated multilayer tablets
|
ES2665467T3
(es)
|
2010-03-29 |
2018-04-25 |
Astellas Pharma Inc. |
Composición farmacéutica de liberación modificada
|
JP5459670B2
(ja)
*
|
2010-05-07 |
2014-04-02 |
塩野義製薬株式会社 |
着色顆粒の色素定着化剤
|
US20130143867A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
AU2013213317B2
(en)
|
2012-01-23 |
2016-06-30 |
Sun Pharmaceutical Industries Limited |
In-situ multilayered tablet technology
|
US10166207B2
(en)
|
2013-06-05 |
2019-01-01 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
AU2014332024B2
(en)
|
2013-10-07 |
2019-09-26 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
RU2016151697A
(ru)
|
2014-06-02 |
2018-07-10 |
Тева Фармасьютикал Индастриз Лтд. |
Расправляемая удерживаемая в желудке лекарственная форма
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
WO2016115253A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Ofcolordo, A Body Corporate |
Insulin mimotopes and methods of using the same
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
CA3001337C
(en)
|
2015-10-09 |
2023-12-12 |
Reckitt Benckiser Llc |
Pharmaceutical formulation
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US9820957B2
(en)
|
2016-03-24 |
2017-11-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of treating autoimmunity
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
ES2966736T3
(es)
|
2016-12-02 |
2024-04-24 |
Clexio Biosciences Ltd |
Sistema de residencia gástrica
|
KR102039345B1
(ko)
*
|
2017-02-01 |
2019-11-01 |
지엘팜텍주식회사 |
프레가발린 함유 고팽윤성 서방성 삼중정제
|
JP7433226B2
(ja)
|
2017-12-01 |
2024-02-19 |
ウルトラジェニクス ファーマシューティカル インク. |
クレアチンプロドラッグ、組成物及びその使用方法
|
US11547839B2
(en)
|
2017-12-04 |
2023-01-10 |
Clexio Biosciences Ltd. |
Long acting gastric residence system
|
JP2021506984A
(ja)
|
2017-12-18 |
2021-02-22 |
トリス・フアルマ・インコーポレーテツド |
トリガーパルス薬物放出を有する胃内滞留型raft形成システムを含む放出調節薬物粉末組成物
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
IL275312B1
(en)
|
2017-12-18 |
2024-05-01 |
Tris Pharma Inc |
GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network
|
US11052060B2
(en)
|
2018-02-12 |
2021-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and methods for treating autoimmunity
|
US11013707B2
(en)
|
2018-03-23 |
2021-05-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Administration of oral methyldopa
|
JP2021523882A
(ja)
*
|
2018-05-15 |
2021-09-09 |
ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド |
低分子egfr阻害剤を含む医薬組成物及びその製造方法
|
CN110214860A
(zh)
*
|
2019-07-10 |
2019-09-10 |
聂刘明 |
一种宠物饲料及其制备工艺
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
BR112024001927A2
(pt)
*
|
2021-07-30 |
2024-04-30 |
Evecxia Therapeutics Inc |
Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
|
US11779567B2
(en)
|
2021-10-14 |
2023-10-10 |
Evecxia Therapeutics, Inc. |
Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
WO2023214018A1
(en)
|
2022-05-06 |
2023-11-09 |
Galenix Innovations |
Gastro-retentive swellable sustained release composition
|